HIV-1 Reverse Transcriptase: A Therapeutical Target in the Spotlight
Authors: Castro, H. C.; Loureiro, N. I.V.; Pujol-Luz, M.; Souza, A. M.T.; Albuquerque, M. G.; Santos, D. O.; Cabral, L. M.; Frugulhetti, I. C.; Rodrigues, C. R.
Source: Current Medicinal Chemistry, Volume 13, Number 3, February 2006 , pp. 313-324(12)
Publisher: Bentham Science Publishers
Abstract:Human Immunodeficiency Virus type 1 Reverse Transcriptase (HIV-1 RT) is one of the most important targets for treatment of Acquired Immune Deficiency Syndrome (AIDS). It catalyzes the reverse transcription of HIV-RNA into a double stranded DNA, and the knowledge of its substrate specificity and catalytic mechanism has guided the development of several inhibitors widely used on current HIV/AIDS therapy. However, mutations in HIV-1 RT structure can lead to the emergence of drug-resistant virus strains. The goal of this review is to summarize relevant structural features of HIV-1 RT and its inhibitors in such a way that this cost-effective target in the development of new antiretroviral drugs is particularly highlighted.
Document Type: Research Article
Affiliations: Departamento de Biologia Celular e Molecular, IB, Universidade Federal Fluminense (UFF), Outeiro Sao Joao Batista, Niteroi, RJ, 24001-970, Brazil.
Publication date: February 1, 2006
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.